Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT04009499 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04009499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04009499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2019
Completion date
May 26, 2026
Enrollment
1,131 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis